PPARγ在非小细胞肺癌中的表达及临床相关性研究

The Expression of Peroxisome Proliferator Activated Receptorγ (PPARγ)In Non-small Cell Lung Carcinoma (Nsclc) and Its Clinical Significance

目的：观察过氧化物酶增殖活化受体（PPARγ）在非小细胞肺癌中的表达和定位。分析PPARγ阳性表达与临床各指标间的关系，探讨PPART在非小细胞肺癌中的意义。方法：随机取60例2000-2003年肺癌石蜡切块，所有病历术前均未行化疗及放疗。并取21例手术患者的病灶旁正常肺组织作对照。采用链霉菌抗生物素蛋白-过氧化物酶（SP）法加高压修复的免疫组化法进行检测。将两组资料相比较，同时分析PPARγ表达情况与肺癌的临床分期、分化程度、有无淋巴结转移、病理类型之间的关系。结果：肺癌、正常肺组织的PPARγ阳性表达率分别为45．00％、4．76％，两者间有显著性差异（P〈0．01）。低分化、中分化、高分化肺癌的PPARγ阳性表达率呈递减趋势，分别为66．67%、61．50％、13．60％，差异有显著性（P〈0．01）。结论：PPARγ蛋白高水平表达是非小细胞肺癌区别于正常肺组织的标志之一，可能参与了肺癌演变的生物学机制，PPAR7染色阳性随分化程度降低和伴淋巴结转移呈上升趋势，且前者有显著性差异，由此可推测PPARγ可能与肿瘤恶性程度有关，可作为判定肺癌预后的指标之一。同时也为将PPARγ特异性配体用于治疗肺癌提供了重要的理论依据。

Objective：To investigate the expression of＇ peroxisome proliferator activated receptorγ （PPARγ）in non-small cell lung carcinoma（Nsclc） and its relation to tumor histological type, grade, differentiation and metastasis of lymph nodes. To investigate the significance of PPARγ in Nsclc. Methods： Sixty pathological primary tumor specimens in random from surgerical patients with Nsclc during 2000 to 2003, none treated previously by chemotheraphy or radiation, as well ad 21 normal lung tissues as controls were examined. Streptavidin-peroxidase （SP） and high pressure immunohistochemical methods were adopted to examine the PPARγ. Results ： Positive PPARγ expression was observed in 27 out of 60 cases of Nsclc examimed（45%） and in 1 out of 21 normal lung tissues （4.76 % ）. There was significant difference between two groups （P〈0.01, respectively）. Compared with those in high and moderate differentiation, expression of PPARγ of those in low differentiation showed an ascending tendency, There was a significant difference （P 〈0.01, respectively）. Conclusion： High positive PPARγ expression is one of signals differentiating Nsclc cases from normal lung tissues. PPARγ possibly participate the biological mechanisms in progression of Nscle, PPAR7 was inferred to correlate with the carcinogenic malignant extent, possibly judging the prognosis. Our results provided the important basis of applying PPAR7 leg- ends to therapy lung cancer in future.